Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Nov 21;19(11):e0312141. doi: 10.1371/journal.pone.0312141

Immune complex deposition promotes NK cell accumulation in the kidney

Abigail De la Cruz 1,2, Marco Garcés 1,3, Emiliano Larios 1,3, Iris K Madera-Salcedo 1, José C Crispín 1,4, Florencia Rosetti 1,*
Editor: Deborah S Cunninghame Graham5
PMCID: PMC11581347  PMID: 39570975

Abstract

In systemic lupus erythematosus, immune complexes deposited in the kidney vasculature represent a potent inflammatory trigger with a high potential to progress to glomerulonephritis and organ failure. These immune complexes can be recognized by multiple effector cells via complement and Fcγ receptors. The transcriptome of CD16-bearing NK cells has been documented in kidneys from patients with SLE. In this study, we show that NK cells accumulate in the kidney in response to immune complex deposition and modulate the behavior of local T cells. Depletion of NK cells transiently ameliorated disease, suggesting NK cells may play a role in lupus nephritis and other immune complex-mediated conditions.

Introduction

Immune complex (IC) deposition represents the main inflammatory trigger of many types of glomerulonephritis. Patients with systemic lupus erythematosus (SLE), a systemic autoimmune disease, produce copious amounts of autoantibodies that deposit in the glomerular vasculature and accumulate as IC within the glomerular basement membrane [1]. In consequence, about 40% of patients with SLE develop lupus nephritis, a condition in which the glomerular and tubule-interstitial compartments of the kidney develop chronic inflammation that causes structural damage and gradual loss of function. Lupus nephritis is an ominous manifestation of SLE, as up to 20% of patients will evolve to end-stage renal disease within 10 years of diagnosis [2, 3].

Within glomeruli, deposited IC initiate inflammation by activating complement. Immunoglobulin and activated complement represent powerful stimuli for neutrophils who engage IC through complement (i.e., CD11b) and IgG receptors (FcγRs). Neutrophil interaction with glomerular ICs is a key pathogenic element, as its inhibition completely avoids the development of kidney injury in several models of nephritis induced by IC deposition [4, 5]. Nevertheless, neutrophil infiltration is not frequently observed in kidney biopsies from patients with lupus nephritis. Even karyorrhexis, an indicator of local neutrophil death, is an infrequent histological finding [6]. Absence of neutrophils has been suggested to be due to their short life, and/or their transient participation during establishment of disease. Transcriptional studies performed in kidneys from patients with lupus nephritis that have undergone sequential biopsies, have shown expression of neutrophil-related transcripts such as ITGAM, ITGB2, and CEACAM8. Their presence correlates with poor response to standard treatment [7]. Single cell RNA analyses have provided us with a more detailed inflammatory landscape of kidneys in lupus nephritis. The AMP Consortium, evaluated the single-cell transcriptome of CD45+ cells from kidney biopsies from 24 patients [8]. Neutrophil transcripts were not present, maybe due to the technical difficulties of maintaining neutrophils for their analysis or due to their absence in these biopsies. However, several FcγR-bearing populations were found, in particular inflammatory CD16+ monocytes. Surprisingly, the most abundant cell population observed were NK cells, particularly CD56DIMCD16+ NK cells, that represented 14% of hematopoietic cells in the kidneys. These cells expressed high levels of cytotoxic transcripts such as PRF1, GZMB and GNLY. Although less abundant, CD56BRIGHTCD16- cells were also present, and expressed genes suggestive of tissue-residence such as KIT, TCF7, IL7R and RUNX2 [8]. Due to their pro-inflammatory capacities, CD56DIMCD16+ NK cells could play a relevant role during the initiation or amplification of local inflammation in response to deposited ICs. CD56DIMCD16+ NK cells are efficient producers of cytokines and chemokines and possess potent cytolytic capacities [9]. Classical NK cell activation results from the integration of inhibitory (i.e. KIRs and NKG2A) and activating (NKG2D and NCRs) signals. Their activation threshold is greatly influenced by cytokine stimulation [10]. NK cells can also be activated through CD16 and CD11b, a process that has been mostly studied in the context of antibody-dependent cellular cytotoxicity (ADCC), but their binding to deposited ICs could probably trigger cytotoxicity and IFN-γ secretion as observed in ADCC. Since NK cells lack inhibitory FcγRs, their activation through ICs could represent an intense and long-lasting stimulus within the kidney [9].

Circulating CD56DIMCD16+ NK cells have been described to decrease during active nephritis in patients with SLE. This could be caused by their migration towards target organs. Documentation of their presence in the single cell RNA study of renal biopsies supports this concept [8]. NK cell dynamics during nephritis development has been evaluated in several murine models of SLE. In MRL/lpr mice, peripheral NK cells decrease after disease initiation, and this correlates with an increase in the number of NK cells within the kidney [11]. However, the consequences of NK cell infiltration or their potential role within the target organs during disease pathogenesis remain unknown and could be relevant in the establishment of local inflammation. To explore this hypothesis, we evaluated the dynamics of NK cell infiltration in a murine model of lupus nephritis triggered by IC deposition. We show that renal NK cell abundance increases in response to IC deposition and that their depletion transiently decreases the magnitude of glomerular inflammation.

Materials and methods

2.1 Patients and controls

Peripheral blood samples were obtained from patients with SLE that fulfilled the 2019 EULAR/ACR classification criteria for SLE [12] and were diagnosed with proliferative (n = 16) or membranous (n = 14) lupus nephritis by renal biopsy [13]. Sex- and age-matched (± 5 years) healthy controls (HCs) with no family history of autoimmune diseases were recruited as controls (n = 14). Samples from patients and their matched HCs were obtained, processed, and analyzed simultaneously on the day of collection (from 04-09-2021 to 03-09-2022). The study was approved by the IRB of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (IRE-2686). All participants signed informed consent forms.

2.2 Mice

C57BL/6 mice obtained from Jackson Labs were housed in specific pathogen-free conditions in accordance to the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Institutional Animal Care and Use Committee (IRE-2119 and IRE-1931). Mice between 8–12 weeks of age were used. At indicated times, mice were euthanized in a CO2 chamber. Since glomerulonephritis is asymptomatic, the IACUC committee did not consider it necessary to use analgesia. Mice were monitored daily for signs of discomfort.

2.3 Data from AMP Consortium

We used the AMP Consortium website (www.immunogenomics.io) to visualize the abundance of NK cells within CD45+ cells from the kidneys evaluated in the original AMP Consortium study [8].

2.4 Nephritis induction and evaluation

Anti-glomerular basement membrane (anti-GBM) glomerulonephritis was induced by immunizing mice with sheep IgG in CFA (day -3) and then intravenously (i.v.) injected with 200 μL of sheep nephrotoxic serum (Probetex) (day 0), as previously reported [14]. Mice were euthanized at indicated times for further analysis. For NK cell depletion experiments, mice were intravenously injected with 200 μg of control IgG or anti-NK1.1 (both from BioXCell) on days -1 and 3. Spot urine samples were collected and urine albumin and creatinine were evaluated by ELISA (Bethyl Laboratories) and a chemical assay (Cayman Chemical), respectively. The results are presented as urine albumin to creatinine ratio. Kidneys were fixed in formalin, and paraffin-embedded for analysis. Tissues sections stained for H&E and PAS were blindly evaluated, and a histological score was given based on endocapillary proliferation, leukocyte infiltration and crescents.

2.5 Flow cytometry

Heparinized peripheral blood was obtained by venipuncture. Whole blood was stained with fluorescence-labeled antibodies in the presence of Fc-block. Red blood cells were lysed before analysis.

Murine spleens were disaggregated to obtain a cell suspension, while kidneys were disaggregated after enzyme digestion (collagenase IV and DNAse I; Gibco, Sigma). Red cells were lysed and cell suspension stained for flow cytometry.

Samples were acquired in an Agilent Novocyte Quanteon 4025 flow cytometer and analyzed using the Novoexpress software and FlowJo v10. A complete list of reagents and antibodies used are presented in S1 Table.

2.6 Statistical analysis

Results are expressed as mean ± SEM unless noted otherwise. Graphpad Prism 10.0 was used for statistical analyses. Individual tests were chosen based on data distribution.

Results and discussion

A single cell transcriptomic analysis performed by the AMP consortium, showed that CD56DIMCD16+ NK cells represent a major fraction of hematopoietic cells in kidneys from patients with lupus nephritis (Fig 1A) [8]. Whether these cells correspond to kidney resident NK cells, or to a peripheral NK cell population that migrated into the inflamed tissue is not clear. Further, their role in the establishment of disease, has not been fully explored.

Fig 1. NK cell abundance increases in kidneys in response to deposited ICs.

Fig 1

(A) Cell clusters identified based on single-cell transcriptional analysis in kidneys from patients with SLE, performed by the AMP Consortium, where NK cells represent a significant population of the hematopoietic cells. Identity of the clusters are specified on the right. (B) Experimental approach of the nephrotoxic nephritis model. (C) Evaluation of NK cells in kidneys upon nephritis induction at the indicated days and absolute NK cell numbers (n = 4–7). (D) Representative plots of NK cells in spleen and kidneys after 7 days of treatment with IgG or anti-NK1.1 antibody. (E) Albuminuria after nephritis induction *p = 0.0305, unpaired t-test. (F) Histological analysis of kidneys of control mice or NK cell-depleted mice; scale bars 80μm (upper panels), and 40 μm (lower panels) (G) Flow cytometry analysis of hematopoietic cell infiltrates in the kidney after nephritis induction in the indicated groups. (H) Total numbers of kidney infiltrating CD45+ cells, T cells, CD8+ T cells and DN T cells in control and NK cell-depleted mice at day 7 of nephritis induction, **p = 0.0011, unpaired t-test.

Because NK cells express FcγRs (i.e. CD16), we decided to evaluate the kinetics of kidney NK cells in an IC-driven glomerulonephritis. For this purpose, mice were subjected to the anti-GBM nephritis model, and kidneys were analyzed at different time points after disease induction (Fig 1B). This disease model allowed us to evaluate the kinetics of NK cells and other leukocytes in a time-controlled manner, as IC deposition initiates immediately after the nephrotoxic serum is injected. Surprisingly, NK cells were rapidly recruited to the kidney (Fig 1C). NK cell numbers peaked at day 5 and gradually decreased (Fig 1C). Most of the kidney NK cells expressed CD11b, an indicator of cellular activation, as CD11b+ NK cells have been shown to be robust producers of IFN-γ, granzyme B, and perforin [15, 16].

To explore the role of NK cell recruitment to the kidney during IC-mediated glomerulonephritis, mice were depleted of NK cells using an anti-NK1.1 antibody 24 hours before anti-GBM serum administration. NK cell depletion occurred within hours and was maintained for at least 21 days (Fig 1D). Interestingly, the NK cell-depleted mice showed a delay in disease development, as reflected by a significant decrease (672.6 ± 229 vs. 152.5 ± 43.4, p = 0.0305) in proteinuria at day 7 (Fig 1E). No significant histological differences were found between groups at day 7 (histological score 1.7 ± 0.2 vs. 1.4 ± 0.24; p = 0.34) nor at day 21 (Fig 1F), suggesting that the effect of NK cell depletion was not sufficiently robust to impact pathology. We evaluated whether kidney cell infiltration was modified by NK cell-depletion. While no changes in total CD45+ cell numbers were observed, a tendency towards an increase in CD8+ T cell infiltration was observed in the NK cell-depleted group. This was associated with a significant decrease in TCRβ+CD4-CD8- T cells (double negative T cells; DNT) (Fig 1G, 1H and S1 Fig). DNT cells are a poorly understood T cell subset, expanded in kidneys of patients with SLE, proposed to correspond to self-reactive pro-inflammatory T cells that produce IL-17, IFN-γ, and TNF-α [17].

CD11b expression was evaluated in the few residual NK cells detected after depletion. Although no differences were found at day 7, a trend to higher expression levels was observed in NK cells from mice that received the anti-NK1.1 antibody (mean fluorescence intensity, MFI: 6544 ± 737 vs. 10884 ± 1864; p = 0.07) at day 21. This observation could be relevant as the initial decrease in proteinuria found in the NK-cell depleted group, could have been partially overcome by an enhanced activation of the few remaining NK cells in the mice in which NK cells were depleted.

In summary, these data suggest that NK cells may migrate into kidneys in response to deposited ICs and may play an initial role in the establishment of renal inflammation.

To determine whether the presence of renal IC affect the numbers or phenotype of circulating NK cells, we recruited patients with lupus nephritis and HCs. Since previous reports have noted an effect of age and sex in circulating NK cells [18, 19], the samples obtained by the HCs were age and sex matched. The demographic and clinical characteristics of the included subjects are presented in S2 Table. Because myeloid cells and NK cells can be activated by their interaction with deposited ICs, we hypothesized that cell proportions or activation markers could differ between these groups of cells. Circulating leukocytes were analyzed as presented in S2 and S3 Figs. No differences in cell proportions or phenotypical markers were observed in the analyzed populations (S4 Fig). However, within the NK cell subset, the proportion of CD56BRIGHTCD16- NK cells, showed a tendency to increase (3.5 ± 0.68 vs. 7.7 ± 2; p = 0.16) while CD56DIMCD16+ population tended to decrease in both groups of patients when compared to healthy controls (58.7 ± 5.5 vs. 53.9 ± 4.2; p = 0.5) (Fig 2A). Accordingly, a negative correlation between SLEDAI at diagnosis with the percentage of circulating CD56DIMCD16+ cells was found (r = -0.446; p = 0.042; Fig 2B). These results are in line with previous reports in which the number of total NK cells is lower in patients with SLE compared with HCs, and this reduction is more accentuated in patients with active disease [15, 20, 21] When specific NK subsets have been analyzed, a slight decrease in CD56DIMCD16+ NK cells [22] and an increase in CD56BRIGHTCD16- NK cells, has also been found, particularly in patients with active disease [23]. In addition to these differences in frequency, NK cells from SLE patients seem to be phenotypically different. Expression of CXCR3 and CD57, molecules involved in migration into the kidney, is decreased in CD56DIMCD16+ NK cells from patients with active disease [20, 2426]. In our analysis, the expression of CXCR3 and CD57 was not modified by the presence of disease (Fig 2C). As previously reported [27], we observed that CD56DIMCD16+ NK cells showed a subtle (67.4 ± 5.5 vs. 72.9 ± 5.15) increase in CD11b expression (Fig 2C), suggestive of an active status. CD11b upregulation has been shown to occur in response to increased levels of IL-15 found in active SLE [28]. This could facilitate NK cell migration to target tissues such as the kidney.

Fig 2. Evaluation of NK cells in patients with lupus nephritis.

Fig 2

(A) NK cells were evaluated by flow cytometry in peripheral blood of Healthy controls (HC), and patients with type IV (LN-IV) or type V (LN-V) lupus nephritis. (B) Correlation between CD56DIMCD16+ cells and SLEDAI at diagnosis (Pearson correlation, p = 0.0427). (C) Heatmaps represent the proportion of cells expressing the indicated activation markers analyzed by flow cytometry. The colorimetric scale represents percentage of NK cell subpopulation expressing the indicated marker.

Taken together, our data indicate that NK cells are recruited very early into kidneys upon IC deposition, where they contribute to the initiation of local inflammation. The effects of NK cell depletion were very mild in the murine model used in this study. The fact that NK cells are so abundant in kidneys from patients with lupus nephritis suggests a more relevant role than we were able to demonstrate. This inconsistency could be related to certain characteristics of the chosen experimental model. In particular, mice receive a very large load of immune complexes in a very acute manner. This could influence the type of cells that become activated and the kinetics with which they exert their pathogenic effects, masking the role of NK cells. NK cells depletion in the NZBxNZWF1 model of chronic nephritis also delayed the onset of kidney disease, although the authors attributed the effect to the loss of NK T cells [29]. These data, along with the results of the present study suggest that NK cells might contribute to inflammation in the setting of lupus nephritis. However, the importance of NK cells in the human disease must be further evaluated.

Conclusions

NK cells play an important role in the surveillance against viruses and cancer. However, they can also influence the effector function of other immune cells through the secretion of pro-inflammatory cytokines. In this work, we evaluated circulating leukocytes of patients with lupus nephritis, and found, consistent with previous reports, a decrease in the CD56DIMCD16+ NK cells, that could be explained by their migration into the inflamed kidney, suggesting their participation in the pathophysiology of lupus nephritis. Using a murine model of acute IC-mediated glomerulonephritis, we show that NK cells infiltrate the kidney during the establishment of disease. By depleting NK cells, we show that these cells can modulate the behavior of T cells within the inflamed tissue and might favor the development of disease. These results highlight the importance of a poorly studied cell population on the pathogenesis of an autoimmune disease.

Supporting information

S1 Fig. Lineage markers expression on hematopoietic cells infiltrating kidneys upon induction of nephritis.

Flow cytometry was used to determine leukocyte populations in kidneys at day 7 after induction of the IC-mediated glomerulonephritis. Expression of the indicated (A) myeloid and (B) lymphoid markers on the CD45+ cells, is shown as heatmap in T-Distributed Stochastic Neighbor Embedding (tSNE) plots.

(TIF)

pone.0312141.s001.tif (5.3MB, tif)
S2 Fig. Gating strategy employed to identify myeloid populations in peripheral blood of the indicated donors.

(TIF)

pone.0312141.s002.tif (1.8MB, tif)
S3 Fig. Gating strategy employed to identify NKT, NK CD56BRIGHTCD16- and CD56DIMCD16+ cells in peripheral blood of the indicated subjects.

(TIF)

pone.0312141.s003.tif (2.9MB, tif)
S4 Fig. Evaluation of frequency and expression of activation markers from neutrophil and monocytes cells in patients with lupus nephritis.

(A) Frequency of Neutrophil and Monocytes was evaluated by flow cytometry in peripheral blood of the indicated groups. (B) Heatmaps represent the proportions of the indicated activation markers analyzed by flow cytometry.

(TIF)

S1 Table. Antibodies and reagents used in the study.

(DOCX)

pone.0312141.s005.docx (15KB, docx)
S2 Table. Demographic characteristics of patients and healthy controls included in the study.

(DOCX)

pone.0312141.s006.docx (15.2KB, docx)
S1 Raw data. Data presented in the figures.

(XLSX)

pone.0312141.s007.xlsx (29.4KB, xlsx)

Acknowledgments

We thank MSc. Dámaris P. Romero-Rodríguez from the Laboratorio Nacional Conahcyt de Investigación y Diagnóstico por Inmunocitofluorometría (LANCIDI) of the Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas” for her help with flow cytometry. We thank Mariela Contreras, Marysol González-Yañez, Berenice Díaz and Anahí L. Aguilar-López for their help handling the mouse colonies.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by CONAHCyT through a research grant (A3-S-39996) to FR and a PhD stipend (1045788) to AC. the funding agency, CONAHCyT, had no involvement in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Tsokos GC. Systemic lupus erythematosus, Mechanisms of disease review article. N Engl J Med. 2011;365: 2110–21. doi: 10.1056/NEJMra1100359 [DOI] [PubMed] [Google Scholar]
  • 2.Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55: 252–262. doi: 10.1093/rheumatology/kev311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol. 2016;68: 1432–1441. doi: 10.1002/art.39594 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity. 2008;28: 833–846. doi: 10.1016/j.immuni.2008.04.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Clynes R, Dumitru C, Ravetch J V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 1998;279: 1052–1054. doi: 10.1126/science.279.5353.1052 [DOI] [PubMed] [Google Scholar]
  • 6.Hill GS, Delahousse M, Nochy D, Mandet C, Bariéty J. Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int. 2001;60: 1893–1903. doi: 10.1046/j.1523-1755.2001.00017.x [DOI] [PubMed] [Google Scholar]
  • 7.Parikh S V., Malvar A, Song H, Shapiro J, Mejia-Vilet JM, Ayoub I, et al. Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int. 2022;102: 845–865. doi: 10.1016/j.kint.2022.05.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20: 902–914. doi: 10.1038/s41590-019-0398-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9: 503–510. doi: 10.1038/ni1582 [DOI] [PubMed] [Google Scholar]
  • 10.Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol. 2014;92: 221–229. doi: 10.1038/icb.2013.98 [DOI] [PubMed] [Google Scholar]
  • 11.Spada R, Rojas JM, Pe´rez-Yagu¨e S, Mulens V, Cannata-Ortiz P, Bragado R, et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015;97: 583–598. doi: 10.1189/jlb.4A0714-326R [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71: 1400. doi: 10.1002/ART.40930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Weening JJ D’Agati VD, Schwartz MM, Seshan S V., Alpers CE, Appel GB, et al. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology. 2004;15: 241–250. doi: 10.1097/01.asn.0000108969.21691.5d [DOI] [PubMed] [Google Scholar]
  • 14.Hoppe JM, Vielhauer V. Induction and analysis of nephrotoxic serum nephritis in mice. Methods Mol Biol. 2014;1169: 159–174. doi: 10.1007/978-1-4939-0882-0_15 [DOI] [PubMed] [Google Scholar]
  • 15.Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, et al. Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol. 2011;186: 3421–3431. doi: 10.4049/jimmunol.1000569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Spada R, Rojas JM, Barber DF. Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus. J Leukoc Biol. 2015;98: 479–487. doi: 10.1189/jlb.4RU0315-081RR [DOI] [PubMed] [Google Scholar]
  • 17.Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008;181: 8761–8766. doi: 10.4049/jimmunol.181.12.8761 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Al-Attar A, Presnell SR, Peterson CA, Thomas DT, Lutz CT. The effect of sex on immune cells in healthy aging: Elderly women have more robust natural killer lymphocytes than do elderly men. Mech Ageing Dev. 2016;156: 25–33. doi: 10.1016/j.mad.2016.04.001 [DOI] [PubMed] [Google Scholar]
  • 19.Chidrawar SM, Khan N, Chan YLT, Nayak L, Moss PAH. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing. 2006;3. doi: 10.1186/1742-4933-3-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Henriques A, Teixeira L, Inês L, Carvalheiro T, Gonçalves A, Martinho A, et al. NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. Clin Rheumatol. 2013;32: 805–813. doi: 10.1007/s10067-013-2176-8 [DOI] [PubMed] [Google Scholar]
  • 21.Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum. 2011;63: 1698–1706. doi: 10.1002/ART.30313 [DOI] [PubMed] [Google Scholar]
  • 22.Suárez-Fueyo A, Bradley SJ, Katsuyama T, Solomon S, Katsuyama E, Kyttaris VC, et al. Downregulation of CD3ζ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype. J Immunol. 2018;200: 3077–3086. doi: 10.4049/JIMMUNOL.1700588 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Kärre K, et al. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology. 2009;126: 140–146. doi: 10.1111/j.1365-2567.2008.02887.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Panzer U, Steinmetz OM, Paust HJ, Meyer-Schwesinger C, Peters A, Turner JE, et al. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J Am Soc Nephrol. 2007;18: 2071–2084. doi: 10.1681/ASN.2006111237 [DOI] [PubMed] [Google Scholar]
  • 25.Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol. 2008;19: 1177–1189. doi: 10.1681/ASN.2007111179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116: 3865–3874. doi: 10.1182/blood-2010-04-282301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Lin SJ, Chen JY, Kuo ML, Hsiao HS, Lee PT, Huang JL. Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on Natural Killer Cell and Natural Killer T-Like Cells in Systemic Lupus Erythematosus. Mediators Inflamm. 2016;2016. doi: 10.1155/2016/9675861 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Lin SJ, Kuo ML, Hsiao HS, Lee PT, Chen JY, Huang JL. Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis-regulation with interleukin-15. PLoS One. 2017;12. doi: 10.1371/journal.pone.0186223 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Postól E, Meyer A, Cardillo F, De Alencar R, Pessina D, Nihei J, et al. Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production. Immunology. 2008;125: 184–196. doi: 10.1111/j.1365-2567.2008.02835.x [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Deborah S Cunninghame Graham

13 Aug 2024

PONE-D-24-23278Immune complex deposition promotes NK cell accumulation in the kidneyPLOS ONE

Dear Dr. Rosetti,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 27 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Deborah S. Cunninghame Graham

Academic Editor

PLOS ONE

PONE-D-24-23278

Journal requirements:   

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

 [This work was supported by CONAHCyT through a research grant (A3-S-39996) to FR and a PhD stipend (1045788) to AC].  

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf."

3. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Immune complex deposition promotes NK cell accumulation in the kidney by Abigail de la Cruz et. al

This manuscript provides a clear description the contribution of the build up of NK cells build in the kidney to lupus nephritis. I recommend minor revision.

A couple of points from the reviewers bear special emphasis:

Reviewer 1 makes a good point regarding figure 1 "The authors should clarify further (maybe in the methods) what their contribution to figure 1 was. Did they access data and (re-)analyse?"

I look forward to receiving your revised manuscript.

I agree with reviewer 2, that the quality of the figures needs improving to meet publication quality

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Minor points:

1. Do you have histological analysis of renal tissue from mouse at Day 7 when the mitigating effect of NK depletion is observed, rather than at day 21 when the effect on proteinuria has disappeared?

2. What is the phenotype of the residual NK cells seen in renal material after NK depletion (Fig 1G)? Are these NK cells CD56 bright or dim, are they expressing activation markers?

3. Can you confirm that the correlation of SLEDAI with CD56dim NK cells is with SLEDAI scored at diagnosis rather than at the time of when the sample (for flow cytometry) was taken or are these the same time point?

4. The resolution of the Figures is not great.

Reviewer #2: The authors investigate the present of NK and their subsets in renal tissue from animals with anti-GBM GN as a model for LN. They furthermore investigate peripheral NK cells from SLE patients and controls. They conclude that NK cells infiltrate the kidneys in response to IC deposition where they amplify inflammation.

This referee wonders whether the authors want to discuss the potential future impact of these findings on the prevention of damage, e.g. through modulation of NK cell responses.

The authors should clarify further (maybe in the methods) what their contribution to figure 1 was. Did they access data and (re-)analyse?

What was the sex distribution among healthy controls? Because the number of CD56bright NK cells within peripheral blood decline with increasing age and are more common stable in women, this is important information (doi: 10.1186/1742-4933-3-10; https://doi.org/10.1016/j.mad.2016.04.001). Were SLE patients more commonly female when compared to controls? If so, the authors may even under-estimate differences between groups?

In Figure 2A the authors claim a tendency towards altered NK cell subsets within patients versus controls. The differences appear minor, and it would be helpful to know the p value to assess the statement. In Figure 2C, can the authors quantify their statement that CD11 differs between groups, and a legend to the heat map would be helpful (colour gradient represents expression levels or p values?).

This referee recommends considering this manuscript as a “short article” after addressing minor points outlined above.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Nov 21;19(11):e0312141. doi: 10.1371/journal.pone.0312141.r002

Author response to Decision Letter 0


22 Aug 2024

Responses to all reviewer's comments are included in a point-by-point response

Attachment

Submitted filename: Response to Reviewers.docx

pone.0312141.s008.docx (19.3KB, docx)

Decision Letter 1

Deborah S Cunninghame Graham

1 Oct 2024

Immune complex deposition promotes NK cell accumulation in the kidney

PONE-D-24-23278R1

Dear Dr. Rosetti,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Deborah S. Cunninghame Graham

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for your revised manuscript. I am pleased to inform you that the reviewers are happy that you have addressed all their questions.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: All of my questions have been addressed, and I feel this manuscript is worth publishing. The project is sound, well executed and approrpiately discussed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Christian Hedrich

**********

Acceptance letter

Deborah S Cunninghame Graham

8 Oct 2024

PONE-D-24-23278R1

PLOS ONE

Dear Dr. Rosetti,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Deborah S. Cunninghame Graham

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Lineage markers expression on hematopoietic cells infiltrating kidneys upon induction of nephritis.

    Flow cytometry was used to determine leukocyte populations in kidneys at day 7 after induction of the IC-mediated glomerulonephritis. Expression of the indicated (A) myeloid and (B) lymphoid markers on the CD45+ cells, is shown as heatmap in T-Distributed Stochastic Neighbor Embedding (tSNE) plots.

    (TIF)

    pone.0312141.s001.tif (5.3MB, tif)
    S2 Fig. Gating strategy employed to identify myeloid populations in peripheral blood of the indicated donors.

    (TIF)

    pone.0312141.s002.tif (1.8MB, tif)
    S3 Fig. Gating strategy employed to identify NKT, NK CD56BRIGHTCD16- and CD56DIMCD16+ cells in peripheral blood of the indicated subjects.

    (TIF)

    pone.0312141.s003.tif (2.9MB, tif)
    S4 Fig. Evaluation of frequency and expression of activation markers from neutrophil and monocytes cells in patients with lupus nephritis.

    (A) Frequency of Neutrophil and Monocytes was evaluated by flow cytometry in peripheral blood of the indicated groups. (B) Heatmaps represent the proportions of the indicated activation markers analyzed by flow cytometry.

    (TIF)

    S1 Table. Antibodies and reagents used in the study.

    (DOCX)

    pone.0312141.s005.docx (15KB, docx)
    S2 Table. Demographic characteristics of patients and healthy controls included in the study.

    (DOCX)

    pone.0312141.s006.docx (15.2KB, docx)
    S1 Raw data. Data presented in the figures.

    (XLSX)

    pone.0312141.s007.xlsx (29.4KB, xlsx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0312141.s008.docx (19.3KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES